시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
단클론항체 요법 시장 규모, 점유율, 성장 분석 : 생산별, 공급원별, 치료법별, 투여별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Production (In Vitro, In Vivo), By Source (Human, Humanized), By Therapy, By Administration, By End User, By Region - Industry Forecast 2025-2032
상품코드 : 1622422
리서치사 : SkyQuest
발행일 : 2024년 12월
페이지 정보 : 영문 157 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,901,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,242,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,584,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

단클론항체 요법 시장 규모는 2023년 1,540억 5,000만 달러로 평가되며, 2024년 1,653억 달러에서 2032년 2,904억 4,000만 달러로 예측 기간(2025-2032년) 동안 7.3%의 CAGR로 성장할 것으로 예상됩니다.

세계 단클론항체 요법 시장은 암, 자가면역질환, 심혈관질환 등 만성질환의 유병률 증가에 힘입어 높은 성장세를 보이고 있습니다. 이러한 질환의 치료에서 단클론항체의 효능은 그 채택을 크게 촉진하고 있습니다. 또한 인구 고령화와 생활습관병의 증가는 시장 확대에 박차를 가하고 있습니다. 기술 발전으로 고특이성 항체 생산능력이 강화되어 치료 효과가 향상되고 있습니다. 또한, 맞춤형 의료와 표적 치료의 중요성이 강조되면서 단클론항체 요법에 대한 수요가 증가하고 있으며, 향후 몇 년 동안 이 시장은 지속적으로 성장할 것으로 예상됩니다. 전반적으로, 이러한 추세는 헬스케어 분야에서 단클론항체의 미래가 유망하다는 것을 보여줍니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

단클론항체 요법 시장 규모 : 생산별

단클론항체 요법 시장 규모 : 공급원별

단클론항체 요법 시장 규모 : 치료법별

단클론항체 요법 시장 규모 : 투여별

단클론항체 요법 시장 규모 : 최종사용자별

경쟁 정보

주요 기업 개요

결론과 추천사항

ksm
영문 목차

영문목차

Monoclonal Antibody Therapy Market size was valued at USD 154.05 Billion in 2023 and is poised to grow from USD 165.3 Billion in 2024 to USD 290.44 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global monoclonal antibody therapy market is witnessing robust growth, primarily driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. The effectiveness of monoclonal antibodies in treating these illnesses is significantly boosting their adoption. Furthermore, an aging population coupled with the increase in lifestyle-related diseases is fueling market expansion. Technological advancements have enhanced the production capabilities of highly specific antibodies, thereby improving therapeutic outcomes. Additionally, the growing emphasis on personalized medicine and targeted therapies is amplifying the demand for monoclonal antibody therapies, positioning this market for sustained growth in the coming years. Overall, these trends indicate a promising future for monoclonal antibodies in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segmental Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market is primarily driven by notable advancements in biotechnology and genetic engineering. These developments have been crucial in creating sophisticated monoclonal antibody therapies that exhibit enhanced specificity and efficacy while minimizing side effects. Innovative techniques, including genetic manipulation, enable researchers to tailor antibodies for particular targets, thereby maximizing their therapeutic effectiveness. As a result, these scientific breakthroughs have expanded the applications of monoclonal antibody therapies and significantly improved their success rates in treating various diseases. This continued evolution in biotechnology is essential for the growth and evolution of the monoclonal antibody therapy market.

Restraints in the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market faces several constraints primarily related to potential side effects and safety issues associated with these treatments. Patients may experience infusion-related reactions during administration, which can lead to discomfort and anxiety. Additionally, there is a risk of immunogenicity, where the patient's immune system reacts against the therapy itself, potentially reducing its effectiveness. Off-target effects may also occur, where the antibody interacts with unintended biological targets, leading to adverse outcomes. To mitigate these concerns, it is essential to implement rigorous safety monitoring, thorough risk assessments, and transparent communication regarding potential side effects, thereby upholding patient safety and trust in these therapies.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is witnessing a robust trend towards increasing adoption of personalized and targeted therapies. As healthcare shifts towards individualized treatment plans, monoclonal antibodies are at the forefront of this evolution, effectively treating conditions such as cancer, autoimmune disorders, and infectious diseases. The integration of companion diagnostics, genetic profiling, and biomarker identification enhances the development and prescription of these therapies, ensuring more precise treatments that optimize therapeutic efficacy and reduce adverse effects. This growing emphasis on personalized medicine is expected to drive substantial growth in the monoclonal antibody market, reflecting a transformative approach to disease management.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2025-2032)

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2025-2032)

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2025-2032)

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2025-2032)

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기